Q1 EPS Forecast for Elevance Health Boosted by Analyst

Elevance Health, Inc. (NYSE:ELV - Free Report) - Research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for shares of Elevance Health in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings per share of $11.57 for the quarter, up from their previous forecast of $10.97. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share. Leerink Partnrs also issued estimates for Elevance Health's Q2 2025 earnings at $10.17 EPS, Q2 2026 earnings at $11.83 EPS, FY2028 earnings at $54.20 EPS and FY2029 earnings at $62.23 EPS.

ELV has been the topic of a number of other reports. Baird R W cut shares of Elevance Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 15th. StockNews.com upgraded shares of Elevance Health from a "hold" rating to a "buy" rating in a report on Thursday, March 20th. Argus upgraded Elevance Health from a "hold" rating to a "buy" rating and set a $450.00 target price for the company in a research note on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $485.00 target price on shares of Elevance Health in a research note on Wednesday. Finally, Stephens cut shares of Elevance Health from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $520.00 to $440.00 in a report on Wednesday, January 22nd. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $509.44.

Elevance Health Stock Performance

Shares of NYSE:ELV traded up $12.30 during mid-day trading on Friday, reaching $428.20. The company had a trading volume of 924,551 shares, compared to its average volume of 1,447,023. The company's 50-day moving average price is $417.66 and its 200-day moving average price is $409.25. Elevance Health has a one year low of $362.21 and a one year high of $567.26. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The firm has a market cap of $96.94 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 1.18 and a beta of 0.77.

Elevance Health (NYSE:ELV - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The company reported $11.97 EPS for the quarter, beating the consensus estimate of $10.60 by $1.37. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. The company had revenue of $48.77 billion during the quarter, compared to the consensus estimate of $46.26 billion.

Insiders Place Their Bets

In other news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares of the company's stock, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ronald W. Penczek sold 443 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the sale, the chief accounting officer now directly owns 1,847 shares of the company's stock, valued at approximately $766,745.11. This represents a 19.34 % decrease in their position. The disclosure for this sale can be found here. 0.29% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Elevance Health

Institutional investors have recently bought and sold shares of the business. Accredited Wealth Management LLC acquired a new position in shares of Elevance Health in the 4th quarter valued at about $25,000. Flagship Wealth Advisors LLC purchased a new position in Elevance Health during the fourth quarter valued at $26,000. Riverview Trust Co lifted its stake in Elevance Health by 1,340.0% in the 1st quarter. Riverview Trust Co now owns 72 shares of the company's stock valued at $31,000 after buying an additional 67 shares in the last quarter. WealthTrak Capital Management LLC purchased a new position in Elevance Health in the 4th quarter valued at $29,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Elevance Health during the fourth quarter worth $30,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.